2 ms·
It would appear that the authors are selling a book on this topic, which explains the BMJ article. And I'm not sure their premise is all that accurate. If the
by refurb 5y ago
It would appear that the authors are selling a book on this topic, which explains the BMJ article.
And I'm not sure their premise is all that accurate. If they think the FDA is in the pocket of pharmaceutical companies, that runs entirely counter to my experience. I can recall plenty of times where we'd suggest a change to a filing and the FDA response was "nope, changes denied". If you think the low level reviewers of submissions are secretly pulling the strings for Pfizer, you'd be wrong.
And in terms of the quality of publications - this is nothing new. There has always been a robustness to clinical trials. That's why the NCCN guidelines for cancer treatment actually rate the clinical evidence from Category 1 (strongest) to Category 3 (no evidence whatsoever).